Literature DB >> 9802746

Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM.

C M Forsblom1, P H Groop, A Ekstrand, K J Tötterman, T Sane, C Saloranta, L Groop.   

Abstract

OBJECTIVE: Our objective was to establish the clinical, genetic, metabolic, and immunologic risk factors for the progression of the albumin excretion rate (AER) in normoalbuminuric NIDDM patients. RESEARCH DESIGN AND METHODS: We recruited 108 NIDDM patients with normal AER after a diabetes duration of 9 years to participate in a prospective 9-year follow-up. In addition to conventional clinical and metabolic variables, we assessed microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (coronary heart disease, peripheral vascular disease) diabetic complications, genetic markers (HLA genotypes), and organ-specific autoimmune markers, including islet cell antibodies. Multiple logistic regression was used to determine independent predictors of progression of AER.
RESULTS: A total of 21 patients (19%) died during the follow-up. There was an overrepresentation of men (61 vs. 39%; P = 0.044) and smokers (55 vs. 27%; P = 0.01) in patients who progressed to micro- or macroalbuminuria versus those who did not progress. In addition, progressors had higher fasting plasma glucose (P = 0.002) and HbA1 (P = 0.0002) concentrations at baseline than did nonprogressors. Neuropathy was more often seen in progressors than in nonprogressors at baseline (53 vs. 16%; P = 0.0004). Frequency of HLA genotypes and autoimmune markers did not differ between progressors and nonprogressors. In a multiple logistic regression analysis, HbA1 (P = 0.0005) and a history of smoking (P = 0.011) were independent predictors of progression of AER.
CONCLUSIONS: This study reemphasizes the importance of poor glycemic control and smoking as independent risk factors for progression of AER. Furthermore, development of micro- or macroalbuminuria in NIDDM was associated with neuropathy and male sex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802746     DOI: 10.2337/diacare.21.11.1932

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  15 in total

1.  Silent diabetic nephropathy.

Authors:  Katia López-Revuelta; Patricia Peña Galdo; Ramona Stanescu; Leticia Parejo; Carmen Guerrero; Elia Pérez-Fernández
Journal:  World J Nephrol       Date:  2014-02-06

2.  A longitudinal study of risk factors for incident albuminuria in diabetic American Indians: the Strong Heart Study.

Authors:  Jiaqiong Xu; Elisa T Lee; Richard B Devereux; Jason G Umans; Jonathan N Bella; Nawar M Shara; Jeunliang Yeh; Richard R Fabsitz; Barbara V Howard
Journal:  Am J Kidney Dis       Date:  2008-03       Impact factor: 8.860

3.  The incidence of microalbuminuria and its associated risk factors in type 2 diabetic patients in isfahan, iran.

Authors:  Massoud Amini; Hassan Safaei; Ashraf Aminorroaya
Journal:  Rev Diabet Stud       Date:  2008-02-10

4.  A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.

Authors:  S S Roscioni; D de Zeeuw; M E Hellemons; H Mischak; P Zürbig; S J L Bakker; R T Gansevoort; H Reinhard; F Persson; M Lajer; P Rossing; H J Lambers Heerspink
Journal:  Diabetologia       Date:  2012-10-20       Impact factor: 10.122

5.  Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes.

Authors:  Merel E Hellemons; Magdalena Mazagova; Ron T Gansevoort; Robert H Henning; Dick de Zeeuw; Stephan J L Bakker; Hiddo J Lambers-Heerspink; Leo E Deelman
Journal:  Diabetes Care       Date:  2012-07-18       Impact factor: 19.112

6.  A microalbuminuria threshold to predict the risk for the development of diabetic retinopathy in type 2 diabetes mellitus patients.

Authors:  Haibing Chen; Zhi Zheng; Yan Huang; Kaifeng Guo; Junxi Lu; Lei Zhang; Haoyong Yu; Yuqian Bao; Weiping Jia
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

7.  Two urinary peptides associated closely with type 2 diabetes mellitus.

Authors:  Man Zhang; Guangzhen Fu; Ting Lei
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

8.  Diabetic nephropathy.

Authors:  Themis Zelmanovitz; Fernando Gerchman; Amely Ps Balthazar; Fúlvio Cs Thomazelli; Jorge D Matos; Luís H Canani
Journal:  Diabetol Metab Syndr       Date:  2009-09-21       Impact factor: 3.320

9.  Albuminuria Testing in Hypertension and Diabetes: An Individual-Participant Data Meta-Analysis in a Global Consortium.

Authors:  Jung-Im Shin; Alex R Chang; Morgan E Grams; Josef Coresh; Shoshana H Ballew; Aditya Surapaneni; Kunihiro Matsushita; Henk J G Bilo; Juan J Carrero; Gabriel Chodick; Kenn B Daratha; Simerjot K Jassal; Girish N Nadkarni; Robert G Nelson; Christoph Nowak; Nikita Stempniewicz; Keiichi Sumida; Jamie P Traynor; Mark Woodward; Yingying Sang; Ron T Gansevoort
Journal:  Hypertension       Date:  2021-08-09       Impact factor: 9.897

Review 10.  Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor.

Authors:  Matthew R Weir
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-03       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.